Zheng Quan Zhi Xing·2025-08-18 11:25Core Viewpoint - The company has decided to extend the investment timeline for certain fundraising projects, specifically the "Drug Clinical Research Project," to align with actual progress and strategic goals, without altering the project's content or financial commitments [3][6][8]. Fundraising Overview - The company raised a total of RMB 1,334,792,400.00 through the issuance of 30,090,000 shares at RMB 44.36 per share, with a net amount of RMB 1,222,708,416.51 after deducting issuance costs [1][2]. - The funds are stored in a dedicated account, and a regulatory agreement is in place with the sponsor and the bank [1]. Investment Project Details - The company has made adjustments to its fundraising project allocations, including a change in the use of RMB 61 million from the "Marketing Network Construction Project" to fund a new project for its subsidiary [2]. - The total investment for the new project is RMB 10,905 million, with RMB 6,100 million sourced from the adjusted funds [2]. Project Timeline Adjustments - The investment period for the "Drug Clinical Research Project" has been extended by two years, now set to conclude on August 31, 2027 [6][8]. - The project includes two sub-projects: the "Vildagliptin Tablets" and "Morphine Sulfate and Naloxone Controlled-Release Capsules," with the former having completed Phase III trials [6]. Reasons for Delay - The delay is attributed to the need for additional clinical trials for the "Vildagliptin Tablets" to meet submission requirements for market approval, considering competitive market conditions and commercialization risks [6][8]. Impact of Delay - The project delay is deemed a prudent decision that will not adversely affect the company's normal operations or alter the investment's total amount, purpose, or scale [8][9]. Approval Process - The board and supervisory committee have approved the project delays, confirming that no shareholder meeting is required for this decision [8][9]. - Both the board and supervisory committee emphasize that the delay is in the best interest of shareholders and aligns with the company's long-term sustainable development [9]. Sponsor's Review - The sponsor has reviewed the project delay and found that all necessary approval procedures have been followed, with no changes to the project's financial commitments or objectives [9].